Navigation Links
PFC SIGMA Fixed Bearing Knee System Cruciate - Substituting

ProductsPFC SIGMA Fixed Bearing Knee System Cruciate - Substituting
Company DePuy Orthopaedics, Inc.
Item PFC SIGMA Fixed Bearing Knee System Cruciate - Substituting
Features 
  • Patented cam and spine design provides true mechanical substitution for the PCL to produce component rollback
  • Its central location transfers shear forces into compression through center stem of tibial component
  • Provides high liftoff value (16.3mm) before femoral component subluxes over tibial spine
  • Uniform femoral box/tibial spine dimensions across size range provide for interchange-ability, one size up and down.
  • Same component can be used for primary CS or revision procedures with the addition of modular stems and augments
  • Revision procedures do not require any additional bone resection
  • Three offset stem/bolt positions (0mm, +/- 2mm), allows accurate femoral component placement based on IM canal.
  • Rounded coronal shape of posterior stabilized tibial insert maximizes contact area and reduces peak stresses avoiding edge loading with rounded femoral condyles
  • Reinforcement pin helps reinforce against high varus/valgus loads insert is subjected to when collateral support is lacking
    • Description The P.F.C. Sigma Total Knee System is designed to provide the surgeon with surgical solutions for a variety of clinical indications. Based on the clinically successful P.F.C. Total Knee System introduced in 1984, P.F.C. Sigma continues a history of innovation. Indicated for procedures where mechanical substitution is required for the posterior cruciate ligament, the cruciate substituting components may be used for primary or revision procedures. The femoral component is modular, allowing for the addition of stems and augments in revision procedures. SPECIALIST 2 Instruments provide for an easy transition from cruciate retaining to cruciate substituting in revision procedures.
    Info DePuy Orthopaedics, Inc.
    Customer Service: (800) 366-8143
    Web site: http://www.jnjgateway.com/home.jhtml?loc=USENG&page=viewContent&contentId=09008b9880772d01

    Related medicine products :

    1. PFC SIGMA Fixed Bearing Knee System Cruciate - Retaining
    2. PFC SIGMA RP Rotating Platform Knee System
    3. Straight Fixed Core Wire Guides
    4. Small Anatomy Fixed Curve Catheters
    5. Inquiry Fixed Curve Diagnostic Catheters
    6. Webster Small Anatomy Fixed Curve Catheters
    7. Webster Supra CS Decapolar (Coronary Sinus Fixed Curve Catheters)
    8. Explorer ST Fixed Curve Diag. Catheters
    9. Webster Santoro 20 Pole Fixed Curve Catheter
    10. Luma-Cath Lumen Diagnostic Mapping Catheters Fixed and Steerable Curves
    11. Webster Luminal Decapolar (Coronary Sinus Fixed Curve Catheters)
    With its wide orifice tip, the Finntip Wide is designed especially for pipetting fragile cell suspensions and macromolecules like genomic DNA. This tip eliminates the mechanical shearing that causes
    Finntips have been designed to optimize the accuracy and precision of Finnpipettes. The quality of our tip products is widely recognized by customers throughout the world. The Finntip range has been
    The BioCheck LH ELISA is intended for the quantitative determination of luteinizing hormone (LH) in human serum. This assay is useful in the diagnosis and treatment of gonadal dysfunction.
    ... hormone (LH) is a glycoprotein secreted by the an... the intact LH molecule is a noncovalently-linked ...lycoproteins all have homologous alpha-subunits, h...h LH and FSH production and secretion are stimulat...
    Medicine Products:
    (Date:11/22/2008)...is now happening for Medicare Advantage Plans. Th...and may also include Part D Prescription Drug Cove...instant quotes and applications. , ...08 -- MediGap Advisors is pleased to announce open...care Advantage Plans are health plan options that ...
    (Date:11/21/2008)...erm labor , , FRIDAY, Nov. 21 (HealthDay... that activates the uterine muscles for contractio...erapies for preterm labor. , The molecule pros...ace of these uterine muscle cells, keeping them re...archers from Dartmouth Medical School in New Hamps...
    (Date:11/21/2008)...niversity College of Medicine research team led by...er of regulation in the cell division cycle, which...cancer begins. , Wang, an assistant professor of...aid the findings will lead to an improved ability ... new drugs that kill cancer cells by inhibiting ce...
    (Date:11/21/2008)...Call/ -- Heska Corporation,(Nasdaq: HSKA ) toda...y of,Security Analysts, 12th Annual Biotech and S... 1177 Avenue of the Americas, 2nd Floor in New Yor...9:35 a.m. Eastern Time (7:35 a.m.,Mountain Time) ... weeks,following the presentation through a link ...
    Breaking Medicine News(10 mins):Health News:MediGap Advisors Announces Open Enrollment for Medicare Supplement Plans 2
    ...ows that men who are angry or hostile should find ...suffer from an irregular // heart rhythm called at... two upper chambers of the heart quiver instead of...l and form clots, increasing the chance for a stro...
    ...s women reduce their risk of birth defects. Now, n... patients alive.// Researchers say about 31,000 st...-related deaths may have been prevented each year ...lic acid lowers homocysteine levels. People with h...
    ...recent study, researchers say , 20 minutes on an e...ving chest pain // than even minimally invasive pr...dy, 101 men with stable coronary artery disease we...se program or intervention with a stent, which is ...
    ...recent study researchers say the estrogen pills do... to an increased risk of stroke.// Researchers sa...r to increase or decrease the risk of heart diseas...eved to do. Estrogen also does not appear to affec...
    Other Medicine News:
    (Date:11/13/2008)...ds Statins Cut Risk of Heart Attacks, Deaths, RES...ovascular Disease,is the leading cause of death am...eds of millions of dollars and causing untold suff...atal disease - even among those who,weren,t though...ions of people could cut their risk of a,heart att...
    (Date:11/12/2008)...mes D. Watson, Marilyn & James Simons and,Sherry L...., Nov. 12 J. Craig Ven...Venter Institute (JCVI), was,awarded the Double He...) on,November 6th at a gala event in New York City...ng with Dr. James D.,Watson for making each of the...
    (Date:11/12/2008)...Provides Reversible, High-level Platelet ...NEW ORLEANS and SOUTH SAN FRANCISCO, Calif., Nov. ...harmaceutical company developing innovative,drugs ...r and inflammatory,diseases, and cancer, today ann...8, the Company,s novel anti-platelet drug that dir...
    (Date:11/12/2008)... its kind shows no clinically meaningful, differen... nearsightedness, JACKSONVILLE, Fla., Nov. 12 /PR...t in clinically significant acceleration in the de...not cause relevant increases in axial,length or co...the,three-year study, the largest randomized trial...
    Breaking Medicine Technology:Seniors Can Be Heartened by New Study on Statins 2J. Craig Venter, Ph.D. Receives Double Helix Medal from Cold Spring Harbor Laboratory 2Portola Announces Data Showing Its Anti-Platelet Drug Inhibits Platelets in Clopidogrel (Plavix(R)) Non-Responders 2Portola Announces Data Showing Its Anti-Platelet Drug Inhibits Platelets in Clopidogrel (Plavix(R)) Non-Responders 3Soft Contact Lenses Do Not Lead to 'Myopic Creep' in Children, Study Shows 2Soft Contact Lenses Do Not Lead to 'Myopic Creep' in Children, Study Shows 3Chiltern Will Sponsor and Present at the 17th Annual Partnerships With CROs Meeting in Las Vegas April 14 16 2008 16386 1Chiltern Will Sponsor and Present at the 17th Annual Partnerships With CROs Meeting in Las Vegas April 14 16 2008 16386 2Obesity Costs U S Companies as Much as 2445 Billion a Year The Conference Board Reports 16384 1Obesity Costs U S Companies as Much as 2445 Billion a Year The Conference Board Reports 16384 2Obesity Costs U S Companies as Much as 2445 Billion a Year The Conference Board Reports 16384 3MedPage Today 28R 29 Selects iSEEK 28TM 29 to Improve Quality of Patient Care 16382 1MedPage Today 28R 29 Selects iSEEK 28TM 29 to Improve Quality of Patient Care 16382 2MedPage Today 28R 29 Selects iSEEK 28TM 29 to Improve Quality of Patient Care 16382 3MedPage Today 28R 29 Selects iSEEK 28TM 29 to Improve Quality of Patient Care 16382 4ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc 4499 1ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc 4499 2ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc 4499 3ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc 4499 4ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc 4499 5ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc 4499 6ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc 4499 7
    ...s intramuscular injection of peramivir for eight,d...s infection and,inhibited virus replication, suppo...ring a pandemic, MEMPHIS, Tenn., May 01, 2007 /PRN...r might offer humans significant protection,during...ording to,results of mouse studies conducted by in...
    ...ND, Sweden--(BUSINESS WIRE)--May 1, 2007 - Teva,Ph... today,announced that data from a 36-week, randomi...udy demonstrated that an oral 0.6 mg,dose of laqui...esonance imaging (MRI) disease activity by 38 perc...dition, there was a favorable,trend towards reduci...
    Other Medicine Technology:Peramivir Protects Mice From Lethal H5N1 Infection 2Peramivir Protects Mice From Lethal H5N1 Infection 3Laquinimod, a Novel Oral Compound, Showed Significant Reduction in,Disease Activity in Patients with Relapsing-Remitting Multiple,Sclerosis (RRMS) 2Laquinimod, a Novel Oral Compound, Showed Significant Reduction in,Disease Activity in Patients with Relapsing-Remitting Multiple,Sclerosis (RRMS) 3Laquinimod, a Novel Oral Compound, Showed Significant Reduction in,Disease Activity in Patients with Relapsing-Remitting Multiple,Sclerosis (RRMS) 4Laquinimod, a Novel Oral Compound, Showed Significant Reduction in,Disease Activity in Patients with Relapsing-Remitting Multiple,Sclerosis (RRMS) 5Laquinimod, a Novel Oral Compound, Showed Significant Reduction in,Disease Activity in Patients with Relapsing-Remitting Multiple,Sclerosis (RRMS) 6